Skip to main content
ABUS logo

ABUS · Arbutus Biopharma Corp · Executive Compensation

Track ABUS — free
$4.02 -0.05 (-1.23%) At close · Nov 20 Q3 2024 earnings call transcript
Market Cap
$616.24M
Shares
153.29M
Volume · Nov 20 2.99M Avg daily vol (3M) 5.19M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025
Executive Total
Michael J. McElhaugh $3,578,150
Tuan Nguyen $2,416,995
David C. Hastings $2,218,362
Lindsay Androski $1,369,013
Fiscal 2024
Executive Total
Michael J. McElhaugh $2,110,083
David C. Hastings $1,825,846
Michael Sofia $1,820,054
Karen Sims $1,697,375
Tuan Nguyen —
Lindsay Androski —
Fiscal 2023
Executive Total
William Collier $3,385,984
Elizabeth Howard $1,842,723
Michael J. McElhaugh $1,620,485
Michael Sofia $1,614,688
David C. Hastings $1,556,806
Karen Sims —
Fiscal 2022
Executive Total
William Collier $2,645,657
Michael J. McElhaugh $1,315,235
Michael Sofia $1,248,210
Elizabeth Howard —
Fiscal 2021
Executive Total
William Collier $3,215,289
Michael Sofia $1,609,160
David C. Hastings $1,456,535
Michael J. McElhaugh —
Fiscal 2020
Executive Total
William Collier $2,728,324
Michael Sofia $1,243,203
Michael J. McElhaugh $1,087,791
Fiscal 2019
Executive Total
Mark J. Murray $3,780,430
William Collier $2,334,185
Michael Sofia $1,051,388
David C. Hastings $1,010,250
Fiscal 2018
Executive Total
Mark J. Murray $2,527,885
David C. Hastings $1,452,867

Executive changes

Person Change Filed
Roger Sawhney, MD Appointed 2026-05-27
Joseph Bishop Appointed 2026-05-27
Matthew Gline Appointed 2026-05-27
Robert Alan Beardsley Appointed 2026-05-27
Lindsay Androski, JD, MBA, CFA Appointed 2026-05-27
Roger Sawhney Appointed 2025-08-06
Anuj Hasija
“The resignation of Mr. Hasija is not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
Resigned 2025-08-06
David Hastings Terminated 2025-04-03
Michael J. McElhaugh
“None of the departures from the Board described herein are the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
Resigned 2025-02-25
Lindsay Androski Appointed 2025-02-25
Lindsay Androski Appointed 2025-02-25
Anuj Hasija Appointed 2025-02-25
Matthew Gline Appointed 2025-02-25
Robert Alan Beardsley Appointed 2025-02-25
Joseph Bishop Appointed 2025-02-25
Lindsay Androski Appointed 2025-02-25
Melissa V. Rewolinski, Ph.D.
“None of the departures from the Board described herein are the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.”
Resigned 2025-02-25
Keith Manchester, M.D.
“None of the departures from the Board described herein are the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
Resigned 2025-02-25
James Meyers
“None of the departures from the Board described herein are the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
Resigned 2025-02-25
Richard C. Henriques
“None of the departures from the Board described herein are the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.”
Resigned 2025-02-25
Daniel Burgess
“None of the departures from the Board described herein are the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
Resigned 2025-02-25
Michael J. McElhaugh
“None of the departures from the Board described herein are the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
Resigned 2025-02-25
Frank Torti, M.D.
“None of the departures from the Board described herein are the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
Resigned 2025-02-25
Michael J. Sofia Retired 2024-10-11
Dr. Michael Sofia Retired 2024-05-02

Leadership

Key facts CIK 1447028 CUSIP 03879J100 13F (30d) 221 filings 200 filers Visit website Investor relations